nach oben

Erschienen in:

25.10.2016 | Original Article

Changes in pulmonary function and influencing factors after high-dose intrathoracic radio(chemo)therapy

verfasst von: Christina Schröder, Prof. Dr. med. Rita Engenhart-Cabillic, Prof. Dr. med. Dipl.-Phys. Hilke Vorwerk, Dr. med. Michael Schmidt, Dr. med. Winfried Huhnt, Dr. rer. nat. Eyck Blank, Dr. rer nat. Dietrich Sidow, Dr. med. André Buchali

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Using prospectively collected patient-related, dose-related, and pulmonary function test (PFT) data before radiotherapy (RT) and at several follow-up visits after RT, the time course of PFT changes after high-dose radio(chemo)therapy and influencing factors were analyzed.

Materials and methods

From April 2012 to October 2015, 81 patients with non-small-cell lung carcinoma (NSCLC), small cell lung carcinoma (SCLC), or esophageal carcinoma where treated with high-dose radio(chemo)therapy. PFT data were collected before treatment and 6 weeks, 12 weeks, and 6 months after RT. The influence of patient- and treatment-related factors on PFT was analyzed.

Results

Mean forced expiratory volume in 1 s (FEV1) constantly declined during follow-up (p = 0.001). In total, 68% of patients had a reduced FEV1 at 6 months. Mean vital capacity (VC) didn’t change during follow-up (p > 0.05). Mean total lung capacity (TLC) showed a constant decline after RT (p = 0.026). At 6 months, 60% of patients showed a decline in VC and 73% in TLC. The mean diffusion capacity for carbon monoxide (DLCO) declined at 6 and 12 weeks, but recovered slightly at 6 months (p < 0.0005). At 6 months, 86% of patients had a reduced DLCO. After treatment, the partial pressure of CO₂ in the blood (pCO₂) was increased and pO₂ was decreased (p > 0.05). Only the pretreatment PFT classification had a significant influence on the post-RT FEV1.

Conclusion

DLCO seems to be the most reliable indicator for lung tissue damage after thoracic RT. Ventilation parameters appear to be less reliable. Concerning patient- or treatment-related factors, no reliable conclusion can be drawn regarding which factors may be relevant.

Mehta V (2005) Radiation pneumonitis and pulmonary fibrosis in non–small-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys 63:5–24. doi:10.1016/j.ijrobp.2005.03.047 CrossRefPubMed

Ordu AD, Nieder C, Geinitz H et al (2014) Radio(chemo)therapie beim lokal fortgeschrittenem Plattenepithelkarzinom des Ösophagus. Strahlenther Onkol 191:153–160. doi:10.1007/s00066-014-0779-x CrossRefPubMed

Yu W‑W, Zhu Z‑F, Fu X‑L et al (2014) Simultaneous integrated boost intensity-modulated radiotherapy in esophageal carcinoma: early results of a phase II study. Strahlenther Onkol 190:979–986. doi:10.1007/s00066-014-0636-y CrossRefPubMed

Abratt RP, Morgan GW (2002) Lung toxicity following chest irradiation in patients with lung cancer. Lung Cancer 35:103–109. doi:10.1016/S0169-5002(01)00334-8 CrossRefPubMed

Choi NC, Kanarek DJ (1994) Toxicity of thoracic radiotherapy on pulmonary function in lung cancer. Lung Cancer 10:S219–S230. doi:10.1016/0169-5002(94)91685-3 CrossRefPubMed

Ghafoori P, Marks LB, Vujaskovic Z, Kelsey CR (2008) Radiation-induced lung injury. Assessment, management, and prevention. Oncology (Williston Park, NY) 22:37–47 (discussion 52–3)

Zehentmayr F, Wurstbauer K, Deutschmann H et al (2014) DART-bid: dosisdifferenzierte akzelerierte Radiotherapie, 2 × 1,8 Gy täglich. Strahlenther Onkol 191:256–263. doi:10.1007/s00066-014-0754-6 CrossRefPubMed

Krengli M, Sacco M, Loi G et al (2008) Pulmonary changes after radiotherapy for conservative treatment of breast cancer: A prospective study. Int J Radiat Oncol Biol Phys 70:1460–1467. doi:10.1016/j.ijrobp.2007.08.050 CrossRefPubMed

Lopez Guerra LJ, Gomez D, Zhuang Y et al (2012) Changes in pulmonary function after three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, or proton beam therapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 83:e537–e543. doi:10.1016/j.ijrobp.2012.01.019 CrossRefPubMedPubMedCentral

10.

Borst GR, De Jaeger K, Belderbos J et al (2005) Pulmonary function changes after radiotherapy in non-small-cell lung cancer patients with long-term disease-free survival. Int J Radiat Oncol Biol Phys 62:639–644. doi:10.1016/j.ijrobp.2004.11.029 CrossRefPubMed

11.

De Jaeger K, Seppenwoolde Y, Boersma LJ et al (2003) Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 55:1331–1340. doi:10.1016/S0360-3016(02)04389-4 CrossRefPubMed

12.

Abratt RP, Willcox PA (1995) The effect of irradiation on lung function and perfusion in patients with lung cancer. Int J Radiat Oncol Biol Phys 31:915–919. doi:10.1016/0360-3016(94)00513-3 CrossRefPubMed

13.

Jaen J, Vazquez G, Alonso E et al (2006) Changes in pulmonary function after incidental lung irradiation for breast cancer: a prospective study. Int J Radiat Oncol Biol Phys 65:1381–1388. doi:10.1016/j.ijrobp.2006.03.008 CrossRefPubMed

14.

Erven K, Weltens C, Nackaerts K et al (2012) Changes in pulmonary function up to 10 years after locoregional breast irradiation. Int J Radiat Oncol Biol Phys 82:701–707. doi:10.1016/j.ijrobp.2010.12.058 CrossRefPubMed

15.

Miller KL, Zhou S‑M, Barrier RC Jr et al (2003) Long-term changes in pulmonary function tests after definitive radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 56:611–615. doi:10.1016/S0360-3016(03)00182-2 CrossRefPubMed

16.

Stanic S, Paulus R, Timmerman RD et al (2014) No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236. Int J Radiat Oncol Biol Phys 88:1092–1099. doi:10.1016/j.ijrobp.2013.12.050 CrossRefPubMedPubMedCentral

17.

Fan M, Marks LB, Hollis D et al (2001) Can we predict radiation-induced changes in pulmonary function based on the sum of predicted regional dysfunction? J Clin Oncol 19:543–550PubMed

18.

Mehta V (2005) Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys 63:5–24. doi:10.1016/j.ijrobp.2005.03.047 CrossRefPubMed

19.

Yuan ST, Frey K, Gross M et al (2012) Changes in global function and regional ventilation and perfusion on SPECT during the course of radiotherapy in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 82:e631–e638. doi:10.1016/j.ijrobp.2011.07.044 CrossRefPubMed

20.

Ohashi T, Takeda A, Shigematsu N et al (2005) Differences in pulmonary function before vs. 1 year after hypofractionated stereotactic radiotherapy for small peripheral lung tumors. Int J Radiat Oncol Biol Phys 62:1003–1008. doi:10.1016/j.ijrobp.2004.12.050 CrossRefPubMed

21.

Gopal R, Starkschall G, Tucker SL et al (2003) Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 56:114–120. doi:10.1016/S0360-3016(03)00077-4 CrossRefPubMed

22.

Theuws JC, Seppenwoolde Y, Kwa SL et al (2000) Changes in local pulmonary injury up to 48 months after irradiation for lymphoma and breast cancer. Int J Radiat Oncol Biol Phys 47:1201–1208. doi:10.1016/S0360-3016(00)00546-0 CrossRefPubMed

23.

Lopez Guerra LJ, Gomez D, Zhuang Y et al (2012) Change in diffusing capacity after radiation as an objective measure for grading radiation pneumonitis in patients treated for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 83:1573–1579. doi:10.1016/j.ijrobp.2011.10.065 CrossRefPubMed

24.

Bishawi M, Kim B, Moore W, Bilfinger T (2012) Pulmonary function testing after stereotactic body radiotherapy to the lung. Int J Radiat Oncol Biol Phys 82:e107–e110. doi:10.1016/j.ijrobp.2011.01.037 CrossRefPubMed

25.

Marks LB, Munley M, Bentel G et al (1997) Physical and biological predictors of changes in whole-lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys 39:563–570CrossRefPubMed

26.

Allen AM, Henning GT, Haken Ten RK et al (2003) Do dose-volume metrics predict pulmonary function changes in lung irradiation? Int J Radiat Oncol Biol Phys 55:921–929. doi:10.1016/S0360-3016(02)04288-8 CrossRefPubMed

27.

Guckenberger M, Klement RJ, Kestin LL et al (2013) Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 85:1074–1081. doi:10.1016/j.ijrobp.2012.09.016 CrossRefPubMed

28.

Jaen J, Vazquez G, Alonso E et al (2012) Long-term changes in pulmonary function after incidental lung irradiation for breast cancer: a prospective study with 7‑year follow-up. Int J Radiat Oncol Biol Phys. doi:10.1016/j.ijrobp.2012.07.003 PubMed

29.

Theuws JC, Kwa SL, Wagenaar AC et al (1998) Prediction of overall pulmonary function loss in relation to the 3‑D dose distribution for patients with breast cancer and malignant lymphoma. Radiother Oncol 49:233–243CrossRefPubMed

Titel: Changes in pulmonary function and influencing factors after high-dose intrathoracic radio(chemo)therapy
verfasst von: Christina Schröder
Prof. Dr. med. Rita Engenhart-Cabillic
Prof. Dr. med. Dipl.-Phys. Hilke Vorwerk
Dr. med. Michael Schmidt
Dr. med. Winfried Huhnt
Dr. rer. nat. Eyck Blank
Dr. rer nat. Dietrich Sidow
Dr. med. André Buchali
Publikationsdatum: 25.10.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 2/2017
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-016-1067-8

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Changes in pulmonary function and influencing factors after high-dose intrathoracic radio(chemo)therapy

Abstract

Purpose

Materials and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

HNO-Op. auch mit über 90?

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Bildgeführte intensitätsmodulierte Strahlentherapie vermindert die gastrointestinalen Spätfolgen nach Radiotherapie des Prostatakarzinoms

Vertically transmitted HPV-dependent squamous cell carcinoma of the external auditory canal

Prognostic role of patient gender in limited-disease small-cell lung cancer treated with chemoradiotherapy

Analysis of risk factors for pulmonary complications in patients with limited-stage small cell lung cancer

Inklusion von Oxaliplatin in die multimodale Behandlung des lokal fortgeschrittenen Rektumkarzinoms

Stellenwert der postoperativen Körperstereotaxie von Wirbelkörpermetastasen

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

HNO-Op. auch mit über 90?

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Onkologie